Baby formula maker: It could take up to 10 weeks to get product back in stores from affected facility

Baby formula maker: It could take up to 10 weeks to get product back in stores from affected facility


Empty shelves show a shortage of baby formula at a Target store in San Antonio, Texas, May 10, 2022.

Kaylee Greenlee Beal | Reuters

The owner of a key baby formula manufacturing plant said Wednesday it is looking to restart its plant in as little as two weeks — but said it would take between six to eight weeks to get formula products back on store shelves once production gets going again.

The shutdown of the facility, owned by Abbott Laboratories and located in Sturgis, Michigan, has prompted a severe shortage of infant formulas including Similac, Alimentum and EleCare. The plant was shut down in February pending a federal investigation into the deaths of two infants and reports of illnesses among other children who consumed certain baby formula products. The plant remains closed.

In a new statement Wednesday, Abbott said that, subject to Food and Drug Administration approval, it could restart the Sturgis site “within two weeks.” But from the time it brings the facility back online, it would take six to eight weeks before product makes it to store shelves, Abbott said.

“We would begin production of EleCare, Alimentum and metabolic formulas first and then begin production of Similac and other formulas,” it said.

As much as 43 percent of normal supplies of formula were out of stock in U.S. grocery stores in the first week of May, according to data from retail research group Datasembly. The shortage has led to calls for Washington to act. In a statement Tuesday, the FDA said it was expediting import documentation from product overseas to get formula in more swiftly, and was also granting case-by-case waivers to allow the sale of “life-sustaining supplies” of specialty and metabolic formulas.

Abbott also said Wednesday there was no evidence linking its formulas to the infants’ illnesses. Although at least one pathogen linked to the children’s illnesses, Cronobacter sakazakii, was found in environmental testing as part of the FDA’s investigation, it was detected in “nonproduct contact areas of the facility and has not been linked to any known infant illness,” the agency said.

“In all four cases, the state, the FDA and/or CDC tested samples of the Abbott formula that was used by the child,” it said. “In all four cases, all unopened containers tested negative.”

Read the full statement from Abbott here.



Source

Trump signs executive order reclassifying cannabis, opening door to broader weed access
Health

Trump signs executive order reclassifying cannabis, opening door to broader weed access

U.S. President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, D.C., U.S., Dec. 18, 2025. Evelyn Hockstein | Reuters President Donald Trump signed an executive order Thursday directing federal agencies to reclassify marijuana, loosening long-standing restrictions on the drug and marking the most consequential shift in […]

Read More
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound 
Health

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound 

Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.  The company also said it has filed for Food and Drug Administration approval of the daily […]

Read More
Medical supply firm Medline set to debut after biggest IPO of 2025
Health

Medical supply firm Medline set to debut after biggest IPO of 2025

U.S. medical supplies giant Medline is set to debut on the Nasdaq on Wednesday after the biggest initial public offering of the year.  The private equity-owned company priced at $29 per share on Tuesday, raising $6.26 billion in an upsized offering that finishes off a strong year for new listings and bolsters optimism about the […]

Read More